ARCHIVES

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 32 No. 7 | July 31, 2009

Download PDF Visit The Full Archive

Related Articles

Tempero, Johnson To Lead ASCO

March 28, 2003

No Cancer Letter For Next Two Weeks

August 30, 1991

New Drug Approval: Groups Urge FDA To Move Quickly On Herceptin Approval

September 18, 1998

President Calls For Reversing Cuts to Basic Research Budget

January 31, 2014

Policy Of 5,000 Grants Meant As Floor, Not Ceiling, Former White House Advisor Insists

March 8, 1985

Rauscher May Set Up New Office To Monitor, Coordinate RFPs And Grants, Stop Duplication

May 2, 1975